Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOX9 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical, Intravenous, Subcutaneous, Intraperitoneal
01
Overview
SOX9 siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of the SRY-box transcription factor 9 (SOX9) gene. SOX9 is a critical transcription factor involved in embryogenesis, sex determination, and chondrogenesis, but its overexpression is associated with tumor progression, metastasis, and drug resistance in various malignancies, including triple-negative breast cancer (TNBC), colorectal cancer, and lung adenocarcinoma. By utilizing RNA interference (RNAi) to knock down SOX9 expression, SOX9 siRNA inhibits cancer cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT), while promoting apoptosis. It is widely utilized as a research-use-only (RUO) reagent in preclinical studies to investigate the therapeutic potential of targeting the SOX9 pathway.
- Other names
- SOX9 small interfering RNASOX-9 small interfering RNASOX 9 small interfering RNAsi-SOX9si-SOX-9si-SOX 9siSOX9siSOX-9siSOX 9
02
Targets
SRY-box transcription factor 9 mRNASOX9 (SRY-box transcription factor 9)
Beyond the preview
Go deeper on SOX9 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOX9 siRNA.